ClinicalTrials.gg
CompletedNCT04891614Updated Jun 1, 2022

The PRISM Pilot Trial for Post-Traumatic Stress Disorder

An interventional study of PRISM in Post-Traumatic Stress Disorder (PTSD), sponsored by GrayMatters Health Ltd.. Completed at 5 sites in 2 countries. Open to participants aged 22 Years to 65 Years. Per ClinicalTrials.gov, last updated 2022-06-01.

Sponsored by GrayMatters Health Ltd. · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was May 2022, 4 years 5 months ago, and no results have been posted to the registry.
  • Registered 5 months after the study started (first participant enrolled Nov 2020, registered May 2021).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
87
Allocation
Not applicable
Ages
22 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 103 studies in Stress Disorders, Post-Traumatic with a site in Israel — 24 open to participants now, 25 under way, 1 of them phase 3. Stress Disorders, Post-Traumatic · Israel.

Enrollment
30th of 77
87 · median 60
Started
2020
with 5 others
No phase
54 of 103
14 open now
Registered
69th of 103
by date

Among the 103 studies in Stress Disorders, Post-Traumatic with a site in Israel, this one is the 30th largest by enrollment of the 77 interventional ones that give a count, is one of 6 that started in 2020, is one of 54 with no phase, and was the 69th registered.

Stress Disorders, Post-Traumatic

2,689 studies on the registry are indexed under Stress Disorders, Post-Traumatic; 605 are open to participants now.

Browse Stress Disorders, Post-Traumatic studies →

Open to participants now

24 of the 103 studies in Stress Disorders, Post-Traumatic with a site in Israel are open now. Recruiting first, the newest first:

19 more — sign in →

All 24 open studies →

A study can be open while its sites in Israel have not opened yet or have stopped. Only those recruiting at a site in Israel →

Who these studies take

Of the 416 Stress Disorders, Post-Traumatic studies recruiting now, 188 (45%) set no upper age limit and 202 (49%) stop at 75 or younger; 62 take children under 18; 88 take healthy volunteers.

This study: 22 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 103 studies in Stress Disorders, Post-Traumatic with a site in Israel, or all of them as a file.
02

Study summary

A Prospective, Single-Arm, Open-Label Pilot Trial, to Assess Safety and Effectiveness of Process-Instructed Self neuro-Modulation ("Prism"), as an Adjunct to Standard of Care, in Subjects with Post-Traumatic Stress Disorder (PTSD)

Read the detailed description

Prism is a software device intended for neurofeedback (NF) training (i.e. operant condition based on EEG signals, also known as EEG-biofeedback), to be used in combination with a standard computer and supported EEG hardware. For purposes of this training, information for feedback is derived and processed from several EEG channels. Prism provides visual and/or auditory signals that correspond to the patient's computed EEG signal, which serves as a surrogate indicator of achieving a state of reduced amygdala activity.

The study is a Prospective, Single-Arm, Open-Label Pilot Trial, to Assess Safety and Effectiveness of Process-Instructed Self neuro-Modulation ("Prism"), as an Adjunct to Standard of Care, in Subjects with Post-Traumatic Stress Disorder (PTSD).

The study population will include subjects diagnosed with Post-Traumatic Stress Disorder (PTSD) from 1 year to 20 years after index trauma. The total expected enrollment is up to 100 subjects in one or more sites.

The study's primary objective is to assess the safety and effectiveness of fifteen (15) EEG-NF training sessions using the Prism software in reducing PTSD-related symptoms.

03

Conditions studied

  • Post-Traumatic Stress Disorder (PTSD)

Keywords

  • PTSD
04

Who can participate

Ages eligible
22 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Ages 22 to 65
  2. Any gender
  3. Diagnosis of PTSD, established according to the , Fifth Edition (DSM-V)
  4. 1 to 20 years since index trauma
  5. Ability to give signed,
  6. Normal or corrected-to-normal vision
  7. Normal or corrected to normal hearing
  8. Subject is able to adhere to the study schedule

Exclusion criteria

Exclusion Criteria:

  1. Have completed two or more full courses of trauma-focused therapy in the past (i.e., EMDR, Prolong Exposure Therapy, etc.), eligibility will be deemed upon the clinical judgment of the investigator.
  2. Lifetime diagnosis for schizophrenia, schizoaffective disorder, schizophreniform disorder, Bipolar I disorder, or delusional disorder
  3. Any mood disorder and anxiety disorder according to (in addition to those described in Exclusion 2) that is the primary focus of treatment in the last 6 months prior to screening, as per the clinical judgment of the investigator
  4. Lifetime diagnosis of autism, mental retardation at the discretion of the investigator.
  5. Diagnosis of moderate or severe substance use disorder within the last 3 months of screening visit (as defined in DSM-5-substance use disorder) or at screening visit
  6. Any prescribed Benzodiazepine which cannot be ceased for the duration of the study (with a of at least 2 weeks prior to the first Prism training session) or which cannot be replaced with short-acting benzodiazepines that are taken only for sleeping during the night
  7. Any psychotropic medication other than a stable dose of selective serotonin reuptake inhibitors (SSRIs) or serotonin-norepinephrine reuptake inhibitor (SNRIs)
  8. Any change in or initiation of- SSRIs or SNRIs antidepressants within the past 4 weeks. At the time of recruitment, subjects must have no intention of changing their medication or psychotherapy during the study duration
  9. Any suicidal behavior in the past 1 year (i.e. actual attempt, interrupted attempt, aborted attempt, or preparatory acts or behavior) prior to screening and during the screening period
  10. Recent initiation (within the past 3 months) of cognitive-behavioral therapy or any evidence-based PTSD psychotherapy (Cognitive Processing Therapy [CPT], Prolonged Exposure [PE], Eye Movement Desensitization and Reprocessing [EMDR]); continuation of established maintenance supportive therapy will be permitted
  11. Any history of brain surgery, of penetrating, neurovascular, infectious, or other major brain injury, of epilepsy, or of other major neurological abnormality (including a history of traumatic brain injury [TBI] with loss of consciousness for more than 24 hours or posttraumatic amnesia for more than 7 days)
  12. Any unstable medical condition, as per the clinical judgement of the investigator
  13. In process of establishing/changing governmental/institutional compensation payments for PTSD symptoms
  14. Enrollment in another clinical study at screening or within 2 months prior to screening, or intended enrollment within the duration of this study
  15. Women who are pregnant, nursing, or who plan to become pregnant while in the trial
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
87 participants (actual)

Study arms

  • Experimental
    Treatment

    Subjects diagnosed with PTSD will be recruited from the community and from local clinical programs. All subjects will undergo Prism neurofeedback training.

    Device: PRISM

Interventions

  • DevicePRISM

    Subjects will complete 15 neurofeedback training sessions delivered twice per week, on non-consecutive days, over 8 consecutive weeks.

06

What researchers measure

Primary outcomes

  1. Clinician Administered PTSD Scale (CAPS - 5)

    The primary objective of this study is to assess the proportion of subjects who demonstrate clinically meaningful improvement in the Clinician Administered PTSD Scale (CAPS - 5) score from Baseline to the 3 months follow-up visit. Clinically meaningful improvement is defined here as a 6-point reduction or more in the CAPS-5 score.

    Time frame: Baseline visit (Week 1) and 3 month Follow-up visit

Secondary outcomes

  1. PCL-5 response rate

    To assess the proportion of subjects who demonstrate clinically meaningful improvement in the PTSD Checklist for DSM-5 (PCL-5). Clinically meaningful improvement is defined here as a 10-point reduction or more in the PCL-5 score

    Time frame: Baseline visit (Week 1), Post-Intervention Visit (Week 9) and 3 month Follow-up visit

  2. ERQ score

    Change from baseline to Month 3 visit in ERQ score

    Time frame: Baseline visit (Week 1), Post-Intervention Visit (Week 9) and 3 month Follow-up visit

  3. PHQ-9 score

    Change from baseline to Month 3 visit in PHQ-9 score

    Time frame: Baseline visit (Week 1), Post-Intervention Visit (Week 9) and 3 month Follow-up visit

  4. Clinical Global Impression (CGI)

    Change from baseline to Month 3 visit in CGI score

    Time frame: Baseline visit (Week 1), Post-Intervention Visit (Week 9) and 3 month Follow-up visit

Other outcomes

  1. Abbreviated PCL (APCL)

    To assess the change in the score of the abbreviated PCL scale (APCL, assessed weekly during the EFP-NF training period)

    Time frame: through study completion, an average of 8 weeks

  2. learning success of the EFP-based neurofeedback

    To quantify the learning success of the EFP-based neurofeedback (namely: learning volitional down-regulation of the Amyg-EFP signal, over time, during the EFP-NF training period)

    Time frame: through study completion, an average of 8 weeks

  3. Patient satisfaction survey

    To quantify patient satisfaction from the EFP-NF training using survey

    Time frame: through study completion, an average of 5 month

  4. Remission rate

    To assess the Remission rate at post training visit (8-9 weeks) and at the 3 months follow-up visit

    Time frame: Baseline visit (Week 1), Post-Intervention Visit (Week 9) and 3 month Follow-up visit

07

Study locations

5 sites
  • NYU Langone Health
    New York, New York 10016, United States
  • Barzilai Medical Center
    Ashkelon, Israel
  • Rambam Health Care Campus
    Haifa, 3109601, Israel
  • Mental Health Center in Be'er Ya'akov
    Ness Ziona, 70350, Israel
  • Sheba Medical Center
    Ramat Gan, 52621, Israel
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2020 to primary completion in May 2022, 18 months.

Of 1,094 interventional studies with no phase under Stress Disorders, Post-Traumatic, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 53. This study's 18 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
May 6, 2021
First posted
May 18, 2021
StartActual
Nov 29, 2020
Primary completionActual
May 31, 2022
CompletionActual
Jun 1, 2022
Last update
Jun 1, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 1, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04891614
Lead sponsor
GrayMatters Health Ltd.
Responsible party
Sponsor
First posted
May 18, 2021
Start date
Nov 29, 2020
Primary completion
May 31, 2022
Completion
Jun 1, 2022
Last update
Jun 1, 2022

Study contacts

Adar Shani
study director · GrayMatters Health

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion